<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220424054628N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-30</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of dexmedetomidine on cardiovascular response</public_title>
      <acronym></acronym>
      <scientific_title>The effect of two different doses of dexmedetomidine intranasal on the cardiovascular response to laryngoscopy and endotracheal intubation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63124</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Factorial, Purpose: Prevention, Randomization description: In this study, the simple randomization method of block randomization (block
randomization) we will use. Blocking is usually in order
Balance the number of samples assigned to each group
To be used in the study. This feature helps researchers to
Items that require intermediate analyzes during the sampling process
The number of samples assigned to each of the case groups
Study is equal. The size of all the blocks is equal and we are in this
We will have a three-group trial of 6 blocks of 15.
Randomization tools are also used in sequence generation software
Random (software allocation Random) is used that
Random sequence generation software in addition to simple randomization capable
To generate random sequences by block generation method.
For hiding
We avoid concealment allocation
We use the method used to execute the sequence
Random refers to study participants, in a way
That before the individual is assigned, the assigned group is not specified.
With
From opaque envelopes sealed in random sequence
(envelopes opaque, sealed, numbered Sequentially) in
This method uses each of the random sequences created on a card
It is registered and the cards are placed in the letter envelopes in order
To be. In order to maintain a random sequence, also on the outer surface of the envelope
The numbering is done in the same way. Finally the envelope lid
The letters are pasted and placed in a box, respectively. At
Time to start registration of participants, based on the order of entry of the company
Eligible applicants to open one of the envelopes in order
And the assigned group of the participant will be revealed, Blinding description: The researcher, patients and project partner who will perform the statistical analysis will not be aware of the study (triole blind). The grouping of patients will be recorded on a sheet and given to one of the project colleagues.</study_design>
      <phase>3</phase>
      <hc_freetext>Cardiovascular response after laryngoscopy and tracheal intubation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 1 µg / kg dexmedetomidine intranasal at a concentration of 100  µg / ml in a 1cc syringe after injection of anesthetic drug. Intervention 2: Intervention group: 2 µg / kg dexmedetomidine intranasal at a concentration of 100  µg / ml in a 1cc syringe after injection of anesthetic drug. Intervention 3: Control group: Normal saline with a volume equivalent to groups 1 and 2  intranasally.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the effectiveness of dexmedetomidine on the cardiovascular response

When:
Start the access period up to one year after the results are published

To whom:
Researchers

Conditions:
Can be used for secondary studies.

Where to obtain:
Correspond with honarmand@mui.ac.ir.

How to obtain:
Will be sent after receiving the email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azim Honarmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Zahra Hospital, Isfahan University of Medical Sciences, Hezar Jerib St., Azadi Square</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8164945811</zip>
        <telephone>+98 31 3662 4796</telephone>
        <email>honarmand@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azim Honarmand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Al-Zahra Hospital, Isfahan University of Medical Sciences, Hezar Jerib St., Azadi Square</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8164945811</zip>
        <telephone>+98 31 3662 4796</telephone>
        <email>honarmand@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Elective surgery
No airway abnormalities
Requires endotracheal intubation under general anesthesia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of allergy to the studied drug
Difficult Airway
Heart block in ECG
BMI&gt;30
History of obstruction of the nasopharyngeal ducts
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 1 µg / kg dexmedetomidine intranasal at a concentration of 100  µg / ml in a 1cc syringe after injection of anesthetic drug</i_keyword>
      <i_keyword>Intervention group: 2 µg / kg dexmedetomidine intranasal at a concentration of 100  µg / ml in a 1cc syringe after injection of anesthetic drug</i_keyword>
      <i_keyword>Control group: Normal saline with a volume equivalent to groups 1 and 2  intranasally</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heart Rate. Timepoint: before induction of anesthesia and minutes 1, 3, 5, 10. Method of measurement: Cardiac monitor device.</prim_outcome>
      <prim_outcome>Systolic blood pressure. Timepoint: before induction of anesthesia and minutes 1, 3, 5, 10. Method of measurement: In millimeters of mercury using a calibrated barometer.</prim_outcome>
      <prim_outcome>Diastolic blood pressure. Timepoint: before induction of anesthesia and minutes 1, 3, 5, 10. Method of measurement: In millimeters of mercury using a calibrated barometer.</prim_outcome>
      <prim_outcome>Mean arterial pressure. Timepoint: before induction of anesthesia and minutes 1, 3, 5, 10. Method of measurement: In millimeters of mercury using a calibrated barometer.</prim_outcome>
      <prim_outcome>Percentage of oxygen saturation. Timepoint: before induction of anesthesia and minutes 1, 3, 5, 10. Method of measurement: Pulse oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hypotension. Timepoint: Before induction of anesthesia, minutes 1, 3, 5, 10. Method of measurement: In millimeters of mercury using a calibrated barometer.</sec_outcome>
      <sec_outcome>Hypertension. Timepoint: Before induction of anesthesia, minutes 1, 3, 5, 10. Method of measurement: In millimeters of mercury using a calibrated barometer.</sec_outcome>
      <sec_outcome>Bradycardia. Timepoint: Before induction of anesthesia, minutes 1, 3, 5, 10. Method of measurement: Cardiac monitor device.</sec_outcome>
      <sec_outcome>Tachycardia. Timepoint: Before induction of anesthesia, minutes 1, 3, 5, 10. Method of measurement: Cardiac monitor device.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-17</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences, Hezar Jerib St., Azadi Square Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
